Bristol Myers Squibb last week entered a $5.8 billion deal to acquire Mirati Therapeutics. Mirati’s leading drug is its KRAS G12C inhibitor Krazati, according to data from Evaluate Pharma. “With multiple targeted oncology assets including Krazati, Mirati is another important step forward in our efforts to grow our diversified oncology portfolio,” Chris Boerner, BMS’s CEO-elect, said in an Oct. 8 statement. The drug received accelerated approval from the FDA in December 2022 for the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), and Evaluate projects the drug will see $109 million in global sales in 2024. For the treatment of NSCLC, Krazati holds covered or better status for 67% of all insured lives under the pharmacy benefit.